References
- Reference annotations
- * Of interest
- ** Of considerable interest
- Kalkers NF, Ameziane N, Bot JC, et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol. 2002;59(10):1572–1576.
- Ge Y, Grossman RI, Babb JS, et al. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. Am J Neuroradiol. 2002;23(8):1327–1333.
- Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914–1929.
- Scalfari A, Neuhaus A, Daumer M, et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 2013;70(2):214–222.
- Geurts JJ, Calabrese M, Fisher E, et al. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 2012;11(12):1082–1092.
A very interesting review on GM damage and its effect on physical and cognitive disability
- De Stefano N, Matthews P, Filippi M, et al. Evidence of early cortical atrophy in MS Relevance to white matter changes and disability. Neurology. 2003;60(7):1157–1162.
One of the first MRI study on cortical atrophy in MS
- Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler J. 2011;17(9):1098–1106.
An influential paper on the involvement of GM in MS
- Calabrese M, Reynolds R, Magliozzi R, et al. Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study. Mult Scler J. 2014;20:258–258.
- Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7(3):301–316.
- Wiles C, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72(4):440–448.
- Othy S, Hegde P, Topçu S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1–mammalian target of rapamycin axis. J Immunol. 2013;190(9):4535–4541.
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol. 2002;9(6):565–572.
- Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364(9440):1149–1156.
- Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler. 2005;11(4):433–440.
- Fazekas F, Lublin F, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis A dose-finding trial. Neurology. 2008;71(4):265–271.
- Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol. 2004;61(9):1409–1412.
- Kalkers N, Bergers E, Castelijns J, et al. Optimizing the association between disability and biological markers in MS. Neurology. 2001;57(7):1253–1258.
- Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(10):1082–1091.
Large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS
- Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(5):256–266.
- Molyneux P, Kappos L, Polman C. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain. 2000;123(11):2256–2263.
- Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing–remitting multiple sclerosis effect of glatiramer acetate and implications. Brain. 2001;124(9):1803–1812.
- Miller D, Soon D, Fernando K, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390–1401.
- Vidal-Jordana A, Sastre-Garriga J, Rovira A, et al. Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol. 2015;1–10. [Epub ahead of print]
- Cohen J, Radue E-W, Barkhof F, et al. Fingolimod-effect on brain atrophy and clinical/MRI correlations in Three Phase 3 studies-TRANSFORMS, FREEDOMS and FREEDOMS II. Abstract presented at AAN, San Diego, 2013.
- Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338–348.
- Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674–680.
- Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the’treatment era’. Nat Rev Neurol. 2015;11:280–289.
- Tsivgoulis G, Katsanos AH, Grigoriadis N, et al. The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Plos One. 2015;10(3). [Epub ahead of print]
The analysis of MS disease-modifying therapies efficacy
- Zivadinov R, Reder A, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71(2):136–144.
- Zhou J, Payen J-F, Wilson DA, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9(8):1085–1090.
- Sun PZ, Benner T, Copen WA, et al. Early experience of translating pH-weighted MRI to image human subjects at 3 Tesla. Stroke. 2010;41(10 suppl 1):S147–S151.
- Sun PZ, Wang E, Cheung JS. Imaging acute ischemic tissue acidosis with pH-sensitive endogenous amide proton transfer (APT) MRI—correction of tissue relaxation and concomitant RF irradiation effects toward mapping quantitative cerebral tissue pH. Neuroimage. 2012;60(1):1–6.
- Dula AN, Asche EM, Landman BA, et al. Development of chemical exchange saturation transfer at 7T. Magn Reson Med. 2011;66(3):831–838.